Delray Beach, FL, May 29, 2025 (GLOBE NEWSWIRE) — The global drug device combination products market, valued at US$224.70 billion in 2024, stood at US$243.02 billion in 2025 and is projected to advance at a resilient CAGR of 9.3% from 2025 to 2030, culminating in a forecasted valuation of US$379.17 billion by the end of the period. The increasing prevalence of chronic diseases worldwide, coupled with the introduction and approval of innovative advanced therapeutics, is driving significant market expansion. The trend towards advanced drug-device combination products is gaining momentum, influenced by the rising demand for self-administration solutions in home healthcare environments. This shift toward home-based care is largely attributed to the aging population, which has led to a larger demographic of patients managing conditions such as diabetes, obesity, and cancer. Furthermore, favourable reimbursement policies and enhanced healthcare infrastructure are facilitating improved access to these combination products. As a result, sustained growth is anticipated in this market segment over the forthcoming years.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131140423
Browse in-depth TOC on “Drug Device Combination Products Market“
300 – Tables
65 – Figures
300 – Pages
By Based on product type, the market for drug-device combination products can be categorized primarily by product type into injectable drug delivery devices, drug-eluting stents, inhalers, infusion pumps, transdermal patches, drug-eluting balloon catheters, and other product types. Among these, injectable drug delivery devices hold the predominant market share, attributed to their rapid, precise, and efficient medication administration, which is critical for the management of chronic conditions such as diabetes, cancer, and autoimmune diseases. The user-friendly nature of these devices, exemplified by options such as prefilled syringes and autoinjectors, significantly enhances patient compliance through streamlined self-administration. Furthermore, injectables play an essential role in the delivery of biological therapies, which are often incompatible with oral administration due to low bioavailability. The escalating prevalence of chronic diseases coupled with ongoing advancements in injectable technologies further cements their leadership position in the market.
By end user, the drug-device combination products market is categorized based on end-users into several segments: hospitals & clinics, ambulatory surgery centers, long-term care facilities, home care settings, and other users. In 2024, the home care segment accounted for the highest CAGR during the forecast period due to the escalating incidence of chronic conditions, demographic shifts with an aging population, the increasing feasibility of self-administration, technological advancements, and favourable reimbursement policies. The adoption of drug-device combination products is rapidly growing in home care settings, and it is expected to …